Carboplatin: uses, effectiveness, side effects and recommendations

Carboplatin is a chemotherapy drug used to treat various types of cancer. It works by interfering with DNA synthesis in cancer cells, which prevents their growth and division.

Knowing the side effects and precautions when receiving carboplatin treatment is essential for the proper effectiveness of the drug.

 

What is carboplatin and what is it used for?

Carboplatin is a versatile and effective chemotherapeutic agent in the treatment of various types of cancer. Its ability to interfere with DNA synthesis in cancer cells makes it a valuable tool in oncology. In addition, its more manageable toxicity profile compared to other platinum agents, such as cisplatin, makes it preferable in many cases.

  • Ovarian cancer: it is one of the most common treatments for ovarian cancer, especially in advanced or recurrent cases.
  • Lung cancer: it is used for both small cell and non-small cell lung cancer. It is effective in combination with other chemotherapy drugs.
  • Head and neck cancer: as a substitute for cisplatin, carboplatin is used in the treatment of cancers in these areas, primarily when the former often cannot be used in combination with radiation therapy.
  • Bladder cancer: it is a treatment option for bladder cancer, especially when other drugs, such as cisplatin, cannot be administered.
  • Breast cancer: in certain cases, it is used to treat breast cancer, usually in combination with other drugs.
  • Germ cell cancer: includes cancers such as testicular cancer. Carboplatin is effective in these cases, often in combination with other chemotherapeutic agents.
  • Endometrial cancer: also used in the treatment of endometrial cancer.
  • Cervical cancer: used in combination with other treatments for cervical cancer.
  • Brain tumors and neuroblastoma: in some cases, it is used to treat certain types of brain tumors and neuroblastoma, a cancer that begins in nerve cells.

 

Effectiveness of carboplatin in cancer treatment 

The effectiveness of carboplatin treatment varies according to the type of cancer and the stage of the patient. Here we describe some cases:

  • Non-small cell lung cancer (NSCLC): studies have shown that carboplatin-based chemotherapy is as effective as cisplatin-based chemotherapy in prolonging survival in patients with advanced NSCLC. The one-year survival rate and response rate are equivalent between the two treatments.
  • Advanced ovarian cancer: carboplatin, in combination with paclitaxel, is one of the standard treatments and has been shown to significantly improve progression-free survival and overall survival in patients with advanced ovarian cancer.
  • Testicular germ cell cancer: patients with classic stage I seminoma can benefit from 1-2 cycles of carboplatin, adjuvant to surgery, showing a disease-specific survival rate of 99% in localized cases and 73% in metastatic cases.
  • Triple-negative breast cancer: platinum-based chemotherapy, including carboplatin, has been shown to increase pathologic complete response rates in women treated before or after surgery, especially in triple-negative subtypes.

Treatment with carboplatin offers significant promise in improving survival and quality of life in several types of cancer, the choice of treatment and its effectiveness depend on multiple factors, including the type of cancer, stage of disease, and individual patient characteristics.

Factors influencing the effectiveness of carboplatin in cancer treatment 

The effectiveness of carboplatin treatment can be influenced by several factors:

Patient-related factors.

  • General health status: the patient’s overall health, including the presence of other diseases or medical conditions, may affect tolerance and response to treatment.
  • Age: younger patients tend to tolerate chemotherapy better and may have a better response to treatment.
  • Kidney and liver function: the body’s ability to process and eliminate the drug is crucial. Kidney or liver problems can affect the dosage and effectiveness of treatment.

Cancer-related factors

  • Type and stage of cancer: the effectiveness of carboplatin varies depending on the type and stage of cancer. For example, it is more effective in certain types of ovarian and lung cancer.
  • Genetic characteristics of the tumor: the presence of certain genetic mutations or biomarkers can influence the response to treatment.

Treatment-related factors

  • Combination with other drugs: carboplatin is often used in combination with other chemotherapy drugs. The choice of these combination drugs may affect the effectiveness of treatment.
  • Dosage and administration regimen: the dose and frequency of administration of carboplatin are crucial. Dosage adjustments may be necessary to maximize effectiveness and minimize side effects.
  • Toxicity profile: the patient’s ability to tolerate the side effects of treatment may influence the continuity and effectiveness of treatment.

Environmental factors

  • Access to quality medical care: the availability of an experienced medical team and adequate facilities can influence treatment delivery and follow-up.
  • Social and emotional support: support from family, friends and support groups can improve adherence to treatment and the patient’s overall well-being.

 

Use of carboplatin in combination with paclitaxel 

Carboplatin and paclitaxel are two chemotherapy drugs that are often used in combination to treat various types of cancer, especially ovarian cancer.

Combination use in the treatment of ovarian cancer

  • Standard treatment: the combination of carboplatin and paclitaxel is the standard treatment for advanced ovarian cancer. This combination has been shown to be highly effective in improving progression-free survival and overall survival in patients with ovarian cancer.
  • Efficacy: studies have shown that this combination is more effective than the use of carboplatin alone. The addition of paclitaxel increases the response rate and prolongs the time to disease progression.

Other types of cancer

  • Lung cancer: in non-small cell lung cancer, the combination of carboplatin and paclitaxel is also used as first-line treatment, primarily in squamous histologies. This combination has been shown to improve response rates and survival compared to other chemotherapy regimens.
  • Breast cancer: in certain cases of breast cancer, especially in triple negative breast cancer, the combination of carboplatin and paclitaxel is used to increase the pathologic complete response rate prior to surgery.

Benefits of the combination

  • Synergy: the combination of these two drugs takes advantage of their different mechanisms of action to target cancer cells in multiple ways, which may increase the efficacy of treatment.
  • Toxicity profile: although both drugs have side effects, their combination allows doses to be adjusted to maximize effectiveness while managing adverse effects.

Side effects of carboplatin

Carboplatin can cause a variety of side effects.

Side effects described:

  • Nausea and vomiting: these are infrequent and when they occur can be managed with antiemetic drugs.
  • Fatigue: rarely a feeling of tiredness may occur which may not be relieved by rest.
  • Loss of appetite: it is exceptional and when it appears it may lead to weight loss.
  • Taste changes: sometimes food may have a metallic taste.
  • Anemia: decrease in the number of red blood cells.
  • Neutropenia: decrease in the number of white blood cells, increasing the risk of infections.
  • Thrombocytopenia: decrease in the number of platelets, and the occurrence of hemorrhagic phenomena should be monitored.

Other side effects

  • Allergic reactions: include hives, rash, itching, reddening of the skin, difficulty breathing or swallowing, dizziness, weakness or rapid heart rate.
  • Liver problems: changes in liver enzyme levels that may indicate liver damage.

It is important that patients inform their physician of any side effects they experience so that they can be properly managed and treatment adjusted if necessary.

 

Carboplatin precautions and contraindications

Importance of regular check-ups

  • Renal function: carboplatin should be given after confirming that the patient has good renal function. This includes blood tests to measure creatinine levels and other markers of kidney function. Detecting problems early allows treatment to be adjusted to prevent serious damage.

Drug interactions

  • Avoiding dangerous interactions: It is essential that patients inform their physician of all medications they are taking, including over-the-counter drugs, supplements and herbal remedies. Some medications may interact with carboplatin, increasing the risk of serious side effects or reducing the effectiveness of treatment.
  • Examples of interactions: the physician should be aware of all the medications the patient is taking in order to avoid interactions.

Precautions for patients with allergies

  • Allergies to platinum drugs: allergic reactions or intolerances, when rare, may include hives, difficulty breathing, swelling and anaphylaxis.

 

Tips for coping with carboplatin treatment

Recommended lifestyle and diet

  • Hydration: it is essential to drink enough water (at least 2-2.5 liters per day) to maintain good hydration and help the kidneys eliminate the medication.
  • Small, frequent meals: eating small portions throughout the day instead of three large meals can help reduce nausea.
  • Soft, easy-to-digest foods: opting for foods such as rice, bananas, applesauce and toast may be easier on the stomach.
  • Lean proteins: consuming lean proteins such as chicken, fish, eggs and legumes is essential for tissue repair and maintenance of muscle mass.
  • Fruits and vegetables: include a variety of fruits and vegetables in the daily diet. These foods are rich in vitamins, minerals and antioxidants that can strengthen the immune system.
  • Avoid fatty and spicy foods: these can worsen nausea and cause stomach upset.
  • Ginger and mint: ginger and mint can help relieve nausea. You can try ginger or peppermint tea.

Physical activity and mental well-being 

  • Daily walks: walking at a moderate pace for 20-30 minutes a day can improve mood and reduce fatigue.
  • Yoga: yoga combines physical exercise with breathing techniques and meditation, which can help reduce stress and improve flexibility and strength.
  • Low-impact exercise: activities such as swimming or cycling are excellent options for staying active without overtaxing the body.
  • Gentle stretching: gentle stretching can help maintain flexibility and reduce muscle tension.
  • Relaxation techniques: practicing meditation, deep breathing and mindfulness can help calm the mind and reduce anxiety.

In conclusion, carboplatin is a versatile and effective chemotherapeutic agent in the treatment of various types of cancer, including ovarian, lung, breast and other cancers. Its ability to interfere with DNA synthesis in cancer cells makes it a valuable tool in oncology.

However, it is crucial to be aware of its side effects and take the necessary precautions, such as regular check-ups and avoiding interactions with other drugs. With proper management, carboplatin can significantly improve the survival and quality of life of cancer patients.

 

Dr. Rosa María Morera

Radiation Oncology

  • Specialist in Radiation Oncology.
  • Degree in Medicine and Surgery.  Faculty of Medicine, Complutense University of Madrid (2-8-1990).
  • Head of the Radiation Oncology Department, Hospital Universitario La Paz, Madrid.
  • Expert with university micro-credential mention in Physics, Technology and Protontherapy. King Juan Carlos University.
  • Higher University Course in Design and Management of Proton Therapy Centres. King Juan Carlos University.
  • XIX Programme of Senior Management in Health Institutions. IESE Business School. University of Navarra.
  • Master in Administration and Management of Health Services XXIV Edition (2013-2014). Pompeu Fabra University.
  • Doctoral Thesis Reading: ‘Radical thoracic irradiation and pulmonary functional study in patients with locally advanced non-small cell lung cancer. Systematic review and prospective case series’ . Qualification of outstanding ‘cum laude’.
  • Doctorate courses: Complutense University of Madrid (1995-1997).
  • She is a researcher in numerous clinical trials, publishing several national and international scientific articles.

Dr. Jose María Oliver

Breast radiology

  • Breast radiologist and specialist in cryoblation of breast lesions in the IVOQA Breast Unit.
  • Degree in Medicine and Surgery from the University of Navarra (1983-1989). Specialisation via MIR in Radiology. Number 289.
  • Specialist in radiology in several renowned hospitals, international reference and pioneer in the application of cryoablation to breast pathology in Spain.
  • Head of the Breast Radiology Section at the Hospital Universitario La Paz.
  • Member of the Spanish Society of Medical Radiology (SERAM) and the Spanish Society of Diagnostic Imaging (SEDIM).

Dr. Jesús Cañete Gómez

General and Digestive Surgery. Oncological Surgery

  • Graduate in Medicine and Surgery from the University of Seville (2000- 2006).
  • Specialist in colon and rectal cancer surgery using a minimally invasive approach.
  • Training in transanal rectal cancer treatment (TAMIS and TaTME).
    Training in minimally invasive surgery at Jackson Memorial Hospital (Miami).
  • Specialist in General Surgery at Viamed Fatima Hospital, Seville (currently).
  • Doctor of Medicine from the University of Seville (‘cum laude’).
  • Associate Professor at the University of Seville Founder of the surgical team Laparoscopic Surgery Seville – MISS (Minimally Invasive Surgical Solutions) – minimally invasive surgical techniques in scheduled and emergency surgery.
  • He has written numerous publications in journals and books and is a member of the Spanish Society of Obesity Surgery (SECO), as well as the Spanish Association of Surgeons (AEC) and the Andalusian Association of Surgeons (ASAC).

Dr. Juan José Segura Sampedro

General and digestive surgery. Oncological Surgery

  • Degree in Medicine and Surgery from the University of Seville. 2003-2009.
  • Specialist in peritoneal carinomatosis.
  • Doctor of Medicine from the University of Seville (‘cum laude’).
  • Oncological Surgeon in the Section of Peritoneal, Retroperitoneal and Soft Parts Oncological Surgery, Department of General and Digestive System Surgery, Hospital Universitario La Paz, Madrid.
  • Associate Professor of Surgery, Faculty of Medicine, University of the Balearic Islands, Palma de Mallorca.
  • 3IP in the Research Group in Advanced Oncological Surgery, m-Health and Innovation in Surgical Technology, Institute for Health Research of the Balearic Islands (IdISBa), Palma de Mallorca.
  • He has written numerous publications in journals and books and is a member of the Spanish Society of Surgical Oncology (SEOQ), the Spanish Society of Coloproctology (AECP), the Spanish Association of Surgeons (AEC), the European Society of Oncological Surgery (ESSO) and the Spanish Group of Peritoneal Oncological Surgery (GECOP).

Pablo Soto

Specialist in sports training for oncology patients

  • Higher Degree in Dietetics (2020-2022)
  • Treatment and rehabilitation of cancer patients

Dr. Gonzalez Larriba

Medical oncology

  • Professor of Medical Oncology at the Complutense University of Madrid
  • Head of the Medical Oncology Section of the Hospital Clínico San Carlos in possession of the European Certificate in Oncology
  • Recognition of 6 six-year research periods + 1 six-year period of knowledge transfer
  • Master in Oncology Services Management by the University of Alcala de Henares
  • Visiting Professor of Oncology at the University of Palermo (Italy)
  • Multiple stays in international centres (Memorial Sloan Kettering Cancer Center, Gustave Roussy Institute, University of Lyon, Princess Margaret Hospital in Toronto, University of Pittsburgh)
  • Maximum recognition of the Professional Career by the Regional Ministry of Health of the Community of Madrid
  • Director of the Master’s Degree in Genitourinary Tumours at the Complutense University of Madrid
  • Founder and member of the Board of Directors of the Spanish Lung Cancer Group, Spanish Genitourinary Tumour Group and Spanish Melanoma Group
  • Member of the Board of Directors of the Spanish Society of Medical Oncology
  • Miembro de la European Society of Medical Oncology, American Society of Clinical Oncology, International Association for the Study od Lung Cancer, etc.
  • Author of more than 300 scientific articles, 400 conference papers and 60 scientific books, as well as speaker in more than 400 conference papers

Francisco Flores

Physiotherapy

  • Graduate in physiotherapy. UEM.
  • Master’s degree in respiratory physiotherapy. UNIVERSITAT
  • ROVIRA i VIRGILI.
  • MASTER specialist in conservative and invasive physiotherapy of myofascial pain syndrome and fibromyalgia. UAH.
  • SPIROMETRIST by the ERS-SEPAR for the performance and interpretation of SPIROMETRY.
  • MASTER Specialist in intratissue percutaneous electrolysis treatments EPI.
  • Specialist in the use and application of the INDIBA ACTIV system.
  • MASTER Specialist in Biomechanical Analysis, Intervention and Treatment “Check yourMOtion”.
  • NATIONAL CLASSIFIER for athletes with cerebral palsy.
  • NATIONAL CLASSIFIER of athletics for people with physical disabilities.
  • RESEARCH PROJECT: “Respiratory physiotherapy as a treatment for ARVC in high performance athletes”.

Dr. Javier Heras Aznar

BREAST UNIT

  • Graduate in Medicine and Surgery from Universidad Autonoma de Madrid 1992.
  • Specialist via MIR in Family Medicine at Hospital Universitario Ramón y Cajal 1994-1996.
  • Specialist via MIR in OBSTETRICS AND GYNECOLOGY at Hospital Universitario Santa Cristina in Madrid 1997-2001.
  • Specialized in the last 27 years in Gynecological Oncology and Breast Pathology, both malignant and benign, with experience in Oncoplastic Surgery.
  • Specialization Course in Oncoplastic Breast Surgery 2015.
  • Coordinator of the Breast Unit and the Breast Tumors and Gynecology Oncology Committee in Hospital Universitario Infanta Sofía.
  • Main Author of the Breast Unit Accreditation Project (Hospital Universitario Infanta Sofía) 2019-2020.

Dr. Beatriz García-Conde

DIGESTIVE SYSTEM MEDICINE

  • Graduate in Medicine and Surgery.
  • MIR specialisation in Digestive System Medicine, Puerta de Hierro University Hospital in Majadahonda. Currently working at the 12 de Octubre University Hospital.
  • Specialist in capsule endoscopy and in diagnostic and therapeutic endoscopy: chromoendoscopy, colon cancer screening, digestive dilatations, PEG placement, endoluminal vacuum therapy (fistulas/leaks), polypectomy/mucosectomy.
  • She also a general digestive consultant with a Master’s Degree in Neurogastroenterology.

Dr. Micaela Riat Castro Zocchi

DIGESTIVE SYSTEM MEDICINE

  • Graduate in Medicine and Surgery.
  • MIR specialisation in Digestive System Medicine, Princesa Hospital (Madrid).
  • Clinical consultation. Diagnostic and therapeutic endoscopy: Chromoendoscopy, Colon Cancer Screening, Placement of digestive prosthesis (oesophagus, colon), Digestive dilatations, PEG Placement, Endoluminal Vacuum Therapy (fistulas/leaks), Polypectomy/mucosectomy. Experience in Bariatric Endoscopy: Intragastric balloon.

Dr. Diana Fresneda Cuesta

DIGESTIVE SYSTEM MEDICINE

  • Graduate in Medicine and Surgery.
  • MIR specialisation in Digestive System Medicine, Jiménez Díaz Foundation. (Madrid)
  • Clinical consultation. Specialist in Endoscopic Capsule and in Diagnostic and Therapeutic Endoscopy: Chromoendoscopy, Colon Cancer Screening, Ligation of Oesophagus Varices, Placement of digestive prosthesis (oesophagus, colon), Digestive dilatations, PEG Placement, Endoluminal Vacuum Therapy (fistulas/leaks), Polypectomy/mucosectomy. Experience in bariatric endoscopy: intragastric balloon, POSE method and Endo-sleeve with POSE system, etc.

Dr. Teresa Valdés Lacasa

DIGESTIVE SYSTEM MEDICINE

  • Graduate in Medicine and Surgery
  • MIR specialisation in Digestive System Medicine, 12 de Octubre University Hospital (Madrid). Advanced Endoscopy Fellowship (ERCP and digestive prostheses) at Ninewells Hospital (United Kingdom). 2020-2021.
  • Clinical consultation and abdominal ultrasound.
  • Specialist in pancreatico-biliary conditions and therapeutic endoscopy: ERCP, placement of digestive prostheses (oesophagus, duodenum, colon, biliary), digestive dilatations, placement of PEGs, endoluminal vacuum therapy (fistulas/leaks), polypectomy/mucosectomy.

Dr. Andrés J. del Pozo García, MD. PhD.

DUAL SPECIALISATION IN DIGESTIVE SYSTEM MEDICINE / FAMILY AND COMMUNITY MEDICINE

  • Graduate in Medicine and Surgery.
  • Dual specialised training (MIR) at the Princesa University Hospital (Madrid).
  • Specialist in Digestive System Medicine and Specialised in Family and Community Medicine
  • PhD in Medicine from the Autonomous University of Madrid. Cum Laude. 2020.
  • Member of S.E.P.D, S.E.E.D., A.E.G, E.S.G.E, AESPANC, Board Member of GETTEMO; Consultant of Apollo Endosurgery in 2021.

Dr. José María Abadal Villayandre

SPECIALIST IN VASCULAR INTERVENTIONAL RADIOLOGY

  • Graduate in Medicine and Surgery from Navarra University.
  • MIR specialisation in Radiology, Radiodiagnosis at Gregorio Marañón University Hospital.
  • PhD in Radiodiagnosis from the Complutense University of Madrid. Cum Laude Doctoral Thesis.
  • Specialist in Vascular Interventional Radiology, accreditation from the Spanish Society of Interventional Radiology.
  • European Board Interventional Radiology (EBIR) Health Sciences) at Alfonso X el Sabio University. 2010-2014.
  • Medical Director of the “Centro de Radiología y Diagnóstico por Imagen”.
  • Scientific and research activity with numerous publications and research studies.
  • Director and professor of Interventional Vascular Radiology at the I-XI Endo-school. Teaching activity.
  • Member of SERAM (Spanish Society of Medical Radiology), CIRSE (Cardiovascular Interventional Radiology Society Europe), and Secretary of SERVEI (Spanish Society of Interventional Vascular Radiology).

Belén Pérez Peiro. Psychologist

SPECIALIST IN PSYCHO-ONCOLOGY

  • Graduate in Psychology
  • Clinical psychologist, Gregorio Marañón University General Hospital, Psycho-oncology, Gynaecological Psychology, Neuropsychology, Detoxification and Out-patient Hospital, inflammatory bowel disease and teenagers.
  • Clinical activity at the Niño Jesús Children’s University Hospital, Psychiatric and Eating Disorder Units.
  • Expert qualification in Psychosomatic Medicine and Health Psychology.
  • Expert qualification in Psychopathology and Psychiatry from the Spanish Society of Psychosomatic Medicine and Medical Psychology.
  • Specialist qualification in Psychotherapy and projective techniques, both of which are recognised by the Madrid Official Association of Psychologists.

Dr. Ana María Moreno

SPECIALIST IN INTERNAL MEDICINE AND NUTRITIONAL PREHABILITATION

  • Graduate in Medicine and Surgery. 1986– 1992.
  • Extraordinary Graduation Award. 1992.
  • MIR specialisation in Internal Medicine. Number 283.
  • Master’s Degree in Palliative Care from Valladolid University. 2011.
  • University Master’s Degree in Advanced Chronic Nursing and palliative care from Antonio de Nebrija University. 2017.
  • PhD Courses 1993.
  • Extensive professional career in many renowned hospitals.
  • Head of Internal Medicine Services at Viamed Santa Elena (Madrid). September 2021 – Present.
  • Teaching and research work.
  • Numerous publications and papers. Participation in courses and seminars.